# US 2012/0269885 A1 · Vaccine for Modulating Between T1 and T2 Immune Responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269885 A1
- Document ID: US20120269885A1
- Status: Published application
- Kind: A1
- Application number: 13/462,356
- Filed: 2012-05-02
- Published: 2012-10-25
- Earliest claimed: 2001-03-27
- Inventors: Wladyslaw A. Budzynski; R. Rao Koganty; Mark J. Krantz; B. Michael Longenecker
- Web page: https://patentgrep.com/patent/US20120269885A1

## CPC

- C07K 14/4727: {Mucins, e.g. human intestinal mucin}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/06: for tuberculosis
- A61P 31/20: for DNA viruses
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C07K 14/35: from Mycobacteriaceae (F)
- C07K 14/445: Plasmodium
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- C12N 2730/10122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides liposomal vaccines containing immunogenic lipopeptides that are capable of modulating the humoral and cellular immune responses in vivo.

## Claims

### Claim at position 1

-81. (canceled)

### Claim 82

A method for inducing a humoral immune response, comprising administering to an individual a formulation comprising: at least one liposome, which comprises a dilipopeptide, said dilipopeptide comprising at least eleven contiguous amino acids of either SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4, and wherein two amino acids of said dilipopeptide are lipidated.

### Claim 83 (depends on 82)

The method of claim 82 in which each lipidated amino acid is selected from the group consisting of threonine, serine, lysine, arginine and cysteine.

### Claim 84 (depends on 82)

The method of claim 82 wherein the lipidated amino acids are serine or lysine.

### Claim 85 (depends on 82)

The method of claim 82 wherein two adjacent amino acids of the dilipopeptide are lipidated.

### Claim 86 (depends on 82)

The method of claim 82 in which each lipidated amino acid is lipidated with a lipid selected independently from the group consisting of myristyl, palmitoyl and lauryl.

### Claim 87 (depends on 82)

The method of claim 82 wherein each lipidated amino acid is serine or lysine and each lipidated amino acid is lipidated with myristyl or palmitoyl.

### Claim 88 (depends on 82)

The method of claim 82, which further comprises administering an adjuvant.

### Claim 89 (depends on 88)

The method of claim 88, wherein the adjuvant is selected from the group consisting of lipid A, monophosphoryl lipid A, muramyl dipeptide, and IL-2.

### Claim 90 (depends on 88)

The method of claim 88, wherein the adjuvant is lipid A or monophosphoryl lipid A.

### Claim 91 (depends on 82)

The method of claim 82, which further comprises administering a monolipopeptide, wherein the monolipopeptide has one lipidated amino acid and the identical sequence as dilipopeptide.

### Claim 92 (depends on 82)

The method of claim 82, wherein the dilipopeptide elicits a humoral IgG immune response which is detectably greater than the humoral IgG immune response elicited under the same conditions by an otherwise identical monolipopeptide wherein one of the two lipidated amino acids of said dilipopeptide is unlipidated or is omitted.

### Claim 93 (depends on 82)

The method of claim 82, wherein the dilipopeptide comprises eleven contiguous amino acids of SEQ ID NO:2.

### Claim 94 (depends on 82)

The method of claim 82, wherein the dilipopeptide comprises SEQ ID NO:2.

### Claim 95 (depends on 82)

The method of claim 82, wherein the dilipopeptide comprises eleven contiguous amino acids of SEQ ID NO:3.

### Claim 96 (depends on 82)

The method of claim 82, wherein the dilipopeptide comprises SEQ ID NO:3.

### Claim 97 (depends on 82)

The method of claim 82, wherein the dilipopeptide comprises eleven contiguous amino acids of SEQ ID NO:4.

### Claim 98 (depends on 82)

The method of claim 82, wherein the dilipopeptide comprises SEQ ID NO:4.

### Claim 99

A liposomal composition comprising a dilipopeptide, said dilipopeptide comprising at least eleven contiguous amino acids of either SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4, and wherein two amino acids of said dilipopeptide are lipidated.

### Claim 100 (depends on 99)

The composition of claim 99, wherein comprises eleven contiguous amino acids of SEQ ID NO:2.

### Claim 101 (depends on 99)

The composition of claim 99, wherein comprises eleven contiguous amino acids of SEQ ID NO:3.

### Claim 102 (depends on 99)

The composition of claim 99, wherein comprises eleven contiguous amino acids of SEQ ID NO:4.
